COSM supply chain intelligence for Cosmos Health Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Cosmos Health Inc. (COSM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SYNTHESIS-STRUCTURED-COMMODITY-TRADE-FINANCE-LIM | SYNTHESIS-STRUCTURED-COMMODITY-TRADE-FINANCE-LIM | 92% | On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”) as amended on November 16,… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IOANNIS-BIKAS-O-E | IOANNIS-BIKAS-O-E | 92% | Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. |
| PHARMACEUTICAL-LABORATORIES-CANA-S-A | PHARMACEUTICAL-LABORATORIES-CANA-S-A | 90% | In connection with the transaction, the Company issued 99,710 shares of its common stock, based on the fair value of the Company’s stock on the acquisition date. The Company accounted for the transac… |
| BASOTHO-INVESTMENT-LIMITED | BASOTHO-INVESTMENT-LIMITED | 62% | Panagiotis Kozaris (former General operational manager and current employee of Cosmofarm S.A) is one of its directors. General and administrative expenses On November 21, 2023, the Company issued 120… |
| BASOTHO-INVESTMENT-LIMITED-BASOTHO-INVESTMENT-LI | BASOTHO-INVESTMENT-LIMITED-BASOTHO-INVESTMENT-LI | 62% | oc Pharma S.A. as of December 31, 2025, and December 31, 2024, respectively, which concerns trading receivables balances with the Company’s Greek and UK subsidiaries. As of December 31, 2025, a cumul… |
| CHICAGO-ILLINOIS-THE-GROUP | CHICAGO-ILLINOIS-THE-GROUP | 62% | ty loan - ( 4,824,035 ) Proceeds from related party loan - 3,625,007 Payment of loans payable - ( 1,065,000 ) Proceeds from loans payable - 65,000 Payment of lines of credit ( 19,532,735 ) ( 20,975,1… |
| CYPRUS-LIMITED | CYPRUS-LIMITED | 62% | cine platform. On June 30, 2023, the Company acquired Laboratories Holdings (Cyprus) Limited (“Cana”), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana S.A. (“Cana SA”), a… |
| DA-MELISSOTOPI-LTD | DA-MELISSOTOPI-LTD | 62% | classified under “Other Current Liabilities. “Obligations that extend beyond 12 months are classified as “Other Non-Current Liabilities.” NOTE 15 – COMMITMENTS AND CONTINGENCIES Legal Matters From ti… |
| EUROLINK-SECURITIES-LTD | EUROLINK-SECURITIES-LTD | 62% | he pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Gre… |
| HIGHLANDER-SPRING-TRADING-LTD | HIGHLANDER-SPRING-TRADING-LTD | 62% | he pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Gre… |
| ICC-INTERNATIONAL-CANNABIS-CORP | ICC-INTERNATIONAL-CANNABIS-CORP | 62% | the intangible asset will be amortized prospectively over that revised remaining useful life. As of December 31, 2023, no revision to the remaining amortization period of the intangible assets was ma… |
| KINGSBURY-CAPITAL-INVESTMENT-ADVISORS-KINGSBURY- | KINGSBURY-CAPITAL-INVESTMENT-ADVISORS-KINGSBURY- | 62% | he pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Gre… |
| LABORATORIES-HOLDINGS | LABORATORIES-HOLDINGS | 62% | ne platform. On June 30, 2023, the Company acquired Laboratories Holdings (Cyprus) Limited (“Cana”), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana S.A. (“Cana SA”), a G… |
| LAIKI-FACTORS-LTD | LAIKI-FACTORS-LTD | 62% | he pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Gre… |
| MARATHON-GLOBAL-INC | MARATHON-GLOBAL-INC | 62% | ition, the ASU amends the guidance on vintage disclosures to require entities to disclose current period gross write-offs by year of origination for financing receivables and net investments in lease… |
| PLATINUM-POINT-CAPITAL-LLC | PLATINUM-POINT-CAPITAL-LLC | 62% | ancreta LOC”), which is renewed annually and has a current interest rate of 4.10%. The maximum borrowing allowed as of December 31, 2023 and 2022 was $ 1,537,618 and $ 1,487,022 , respectively. The o… |
| SKYPHARM-S-A-DECAHEDRON-LTD | SKYPHARM-S-A-DECAHEDRON-LTD | 62% | tial doubt about the Company’s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its … |
| SMALLER-REPORTING-COMPANY | SMALLER-REPORTING-COMPANY | 62% | m with a significant track record in the pharmaceutical business. In order to achieve our strategic objectives, we have, and will remain, focused on hiring and retaining a highly skilled management t… |
| SYNTHESIS-STRUCTURED-COMMODITY-TRADE-FINANCE-LIM | SYNTHESIS-STRUCTURED-COMMODITY-TRADE-FINANCE-LIM | 62% | the Company’s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its ability to access… |
| ZIP-DOCTOR-INC | ZIP-DOCTOR-INC | 62% | the Company had a VAT net receivable balance of $ 453,619 and $ 534,263 respectively, recorded in the consolidated balance sheets as “Prepaid expenses and other current assets”. Inventories Inventory… |
| ZIPDOCTOR-INC-THE-GROUP | ZIPDOCTOR-INC-THE-GROUP | 62% | tial doubt about the Company’s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| COSM-DEBT | Debt stack $2.8M | 90% | Market cache reports total debt of $2.8M. |
| COSM-DEBT-8806 | Warrants outstanding: 0 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| COSM-DEBT-8807 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |